Health Care Medical

Progenika Biopharma S.A.

Parque Tecnologico de Bizkaia EDIF 801B
48160 Derio Vizcaya
Spain

Phone: +34 94 4064525
Fax: +34 944 064 526

http://www.progenika.com

info@progenika.com

Company Figures
Number of employees 50-99
Year of foundation 2000
Area of business Electronical Equipment / Medical Technology

Diagnostics

Company Profile

Progenika Biopharma S.A.

Progenika Biopharma S.A. is a privately owned Spanish company founded in April 2000, with the aim of designing and developing tools for Personalized Medicine.

The company develops and manufactures novel DNAchips for Genotyping that can be used in the diagnosis and prognosis of human diseases.

More than 60 scientists work at Progenika, whose state of the art facilities are situated in the Bizkaia Technology Park in the outskirts of Bilbao (Spain). Progenika’s fully equipped installations are specifically designed for the production and analysis of DNAchips. This state of the art equipment is backed up by a team of Computer experts who develop the algorithms and software that facilitate the automatic interpretation of DNAchip results.

Proteomika S.L., a subsidiary of Progenika that provides complementary skills in protein biomarker detection. Proteomika is involved in the development of protein arrays for the detection of disease biomarkers in human fluids.

Product Information
03.01.02 DNA diagnosis kits
BLOODchip 19.09.2008

Preemptively determining a patients’ complete blood type profile can prevent alloimmunization issues that arise from mismatched blood transfusions.
BLOODchip uses genotyping to determine over 60 clinically relevant Blood group phenotypes.

It has been designed to decrease the rate of alloimmunization caused by transfusion of incompatible blood.

BLOODchip determines the following Blood group systems: ABO, RHD, RHCE, Kell, Kidd, Duffy, MNS, Colton, Diego and Dombrock

prevent alloimmunization…
The vulnerable patient groups at most risk for alloimmunization and who will benefit the most from BLOODchip are:

Pregnant women who are RHD negative and at risk of maternal alloimmunization;
Multiply transfused patients such as those with sickle cell anemia, thalassemia or those undergoing chemotherapy;
D negative patients that might receive blood incorrectly serotyped as D-negative but are RhD positive variants;
Patients who are Jknull for KIDD who might receive Jka blood incorrectly serotyped as Jknull;
Patients who are Fyb- for Duffy who might receive Fyb weak blood that has been incorrectly classified as Fyb-.

LIPOchip 19.09.2008

Early detection and treatment of FH is crucial to improving patient outcomes
Patients with FH have access to effective treatments that can lower cholesterol levels by up to 60%.

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that affects approximately 1 in 500 persons worldwide.

Clinically, patients with FH have a higher risk of developing coronary artery disease and atherosclerosis at an early age due to mutations on a gene, Low-Density Lipoprotein Receptor (LDLR), which helps remove cholesterol from the blood.

accurate, rapid and cost-effective testing…
According to the American Heart Association and the World Health Organization, genetic testing is the criterion standard for diagnosis. But until LIPOchip, cost effective testing has been a challenge since there are several hundred relevant gene mutations.

LIPOchip solves this problem and allows the accurate, rapid and cost-effective screening for more than 220 mutations in the LDLR and APOB genes. Some of the advantages of a genetic-based confirmation are:

Identification of asymptomatic children and relatives
Earlier treatment
More effective treatment

Greater treatment regimen adherence

PHARMAchip 19.09.2008

Identify genetic variations that impact drug metabolism
By knowing if your genes carry some of these variations, your physician can make better informed decisions regarding the drugs he prescribes for you.

PHARMAchip is an accurate, rapid and cost-effective tool for assessing an individual’s genetic’s background relating to his response to a drug treatment.

It is frequent that people prescribed the same drug won’t benefit from it in the same way. One individual may experience side effects or adverse events. Another might see no or very little theurapeutic effect. And yet another could simply be relieved of his symptoms without any side effect. These individual differences can be explained by genetic factors, among others.

PHARMAchip is a pharmacogenetics tool that can identify genetic variations that impact drug metabolism, including drug targets, transporters, receptors, and enzymes that modify the drug molecules. For more information on how PHARMAchip can help you, please click below.